Long term safety of infliximab

Canadian Journal of Gastroenterology

Volumn 14, Issue SUPPL. C, 2000, Pages

  Schaible, Thomas F ^a  

^a CENTOCOR INC   (United States)

Author keywords

Crohn's disease; Infliximab; Long term use; Safety

Indexed keywords

GASTROINTESTINAL AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY;

ARTICLE; CROHN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; INFUSIONS, INTRAVENOUS;

EID: 0034268094     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/698523     Document Type: Article

References (16)

1. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
2. Present DH, Rutgeerts P, Targan S, et al. Infliximab treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405.
3. Rutgeerts P, D'Haens GR, Targan SR, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
4. van Dulleman HD, van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
5. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 1993;36:1681-90.
6. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
7. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
8. Maini RN, St Clair EW, Breedveld FC, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
9. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000;27:841-50.
10. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;20:1443-53.
11. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9.
12. Siegel SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995;7:15-25.
13. REMICADE package insert. Malvern: Centocor, 1999.
14. Via CS, Rus V, Shustov A, Nguyen, P, Finkelman F. Administration of anti-tumor necrosis factor (TNF) monoclonal antibody (MAB) induces lupus-like autoimmunity in the parent-into-f1 (P-F1) model of acute graft versus host disease (GVHD). Arthritis Rheum 1996;39:5108.
15. Jacob CO, McDevitt HO. Tumor necrosis factor-alpha in murine autoimmune "lupus" nephritis. Nature 1988;331:356-8.
16. ENBRO package insert. Seattle: Immunex Corporation, 2000.